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Although the majority of papillary thyroid carcinoma could be successfully managed by complete surgical resection alone or
resection followed by radioiodine ablation, a small proportion of patients may develop radioiodine-refractory progressive disease
which is not amenable to surgery, local ablative treatment or other treatment modalities. The use of FDG-PET/CT scan for
persistent/recurrent disease has improved the accuracy of restaging as well as cancer prognostication. Given that patients with RAI-
refractory disease tend to do significantly worse than those with radioiodine-avid or non-progressive disease, an increasing number
of phase I and II studies have been conducted to evaluate the efficacy of new molecular targeted drugs such as the tyrosine kinase
inhibitors and redifferentiation drugs. The overall response rate of these drugs ranged between 0–53%, depending on whether the
patients had been previously treated with these drugs, performance status and extent of disease. However, drug toxicity remains a
major concern in administration of target therapies. Nevertheless, there are also ongoing phase III studies evaluating the efficacy
of these new drugs. The aim of the review was to summarize and discuss the results of these targeted drugs and redifferentiation
agents for patients with progressive, radioiodine-refractory papillary thyroid carcinoma.
1. Introduction
Papillary thyroid carcinoma (PTC) is the most common
type of differentiated thyroid carcinoma (DTC) and its age-
adjusted incidence has doubled in the last 25 years [1].
Despite its relatively good prognosis with a 10-year cancer-
specific survival above 90%, locoregional recurrences and
distant metastasis do occur not infrequently [2]. Of the 5–
20% patients who may develop locoregional recurrences,
approximately two-thirds of these recurrences involved the
cervical lymph nodes. On the other hand, up to 10–15%
patients would either present with distant metastasis at
diagnosis or develop distant metastasis some time after
initial treatment [3]. It is not uncommon to encounter
patients with initial persistent locoregional recurrence who
also later develop distant metastasis. Perhaps, this is a sign
of disease progression. Since most patients would have had a
total thyroidectomy and radioiodine (RAI) ablation as their
initial therapy, disease monitoring or surveillance often relies
on regular measurement of thyroglobulin (Tg) and high
resolution neck ultrasound (USG) [4]. FDG-PET/CT scan is
now often used as a staging tool in patients with suspected
disease recurrence.
In terms of treating locoregional recurrence, a formal
selective neck dissection for lymph node recurrence is usually
preferred but at times when certain compartments has been
previously dissected, a focused neck dissection or completion
compartmental neck dissection might be preferred [2].
However, despite the best surgical effort, only approximately
one-third of patients would become biochemically cured
of the disease (i.e., athyroglobulinemia) and therefore, the
American Thyroid Association (ATA) only recommended
surgical removal of clinically significant metastatic lymph
nodes to prevent future locoregional complications [2, 5, 6].
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Other options include percutaneous ethanol injection and
radiofrequency ablation (RFA) as their efficacy have been
shown in several studies [7–9]. The decision for further
adjuvant RAI therapy after reoperative neck dissection
depends on the completeness of the dissection [5]. After
that, local external beam radiation therapy (EBRT) might
be considered in patients with gross unresectable, residual
recurrence in the thyroid bed or lateral neck area. Adjuvant
external beam radiation in patients with residualmicroscopic
disease could achieve a higher 10-year local relapse-free rate
(93% versus 78%) and disease free survival (100% versus
95%) compared with nonradiated patients [10].
In terms of treating patients with distant metastasis,
surgical resection is often not the first treatment modality
unless a patient has a solitary metastasis which is located
near to or in a vital area such as the brain or vertebra. EBRT
might be considered in patients with unresectable painful
bone metastasis or metastatic lesion which might develop
future debilitating complication, for example, fracture,
neurological symptoms, compressing or invading of vital
structures. In patient with brain metastasis not amendable
to surgical resection, whole brain irradiation for multiple
lesion or gamma knife radiosurgery for selected patients
are acceptable options [5, 11]. RAI is often used as the
first-line treatment for patients with distant metastases
because it is highly effective in the treatment of small sized
distant metastases. Although pulmonary pneumonitis and
fibrosis are potential complications which could arise from
repeated high-dose RAI treatment, it is recommended that
pulmonary micrometastases should be treated with RAI
(100–200mCi) therapy and repeated every 6–12 months so
long as the disease continues to concentrate RAI (i.e., RAI-
avid) and responds clinically. RAI is generally recommended
in patients with nonpulmonary RAI-avid distant metastases,
although it might be less effective than pulmonary RAI-avid
metastases [2, 5].
As a result, one of the most controversial and difficult
issues in treating advanced PTC is how to manage non-
RAI-avid disease or RAI-refractory. A patient is defined as
having RAI-refractory disease if there is at least one lesion
without RAI uptake or a lesion has progressed within a year
following RAI treatment or persisted after the administration
of a cumulative activity of more than 600mCi. The current
evidence suggests that RAI is of little benefit in patients
with RAI-refractory disease [12, 13]. Furthermore, repeated
dosage of RAI is associated with dose related complications
like salivary gland damage, dental caries, nasolacrimal duct
obstruction, and secondary malignancy [5, 14]. Although
in the setting of a negative diagnostic RAI scan, small
metastases may demonstrate a small measurable benefit
to RAI (in terms of decreased Tg), it is of no use at
all in large-sized metastases [12, 13]. Therefore, RAI is
generally not recommended in RAI-refractory disease and
the current treatment options aremainly restricted to conser-
vative treatment, metastectomy, symptomatic control (e.g.,
drainage of effusions), endobronchial laser ablation, and/or
external beam radiation in locally advanced carcinoma.
Although age and patient performance status are important
considerations when deciding on which treatment option
might be preferred, with better understanding and advances
in the molecular biology that underlies the development
and progression of advanced PTC, many new molecular
targeted drugs have been examined or are being examined
in the setting of a clinical trial. To date, the available drugs
have been targeting two specific molecular pathways in
thyroid oncogenesis, namely the mitogen-activated protein
kinase (MAPK) pathway and the phosphatidyl-inositol-
tri-phosphate kinase (PI3K) pathway. Figure 1 shows the
main signaling pathways involved in thyroid oncogenesis.
Redifferentiation therapy is a potential alternative for RAI-
refractory disease. Redifferentiating agents could potentially
reactivate the RAI uptake ability of DTC. The aim of
the present paper is to evaluate the efficacy of these new
molecular targeted drugs as well as redifferentiation therapy
in the treatment of RAI-refractory advanced or metastatic
PTC by reviewing the current literature.
2. Approach to Patients with
RAI-Refractory Advanced PTC
Before starting novel therapy, patients with RAI refractory
disease should be accurately characterized in terms of age,
performance status, histology, disease extent and location,
and progression rate [16]. Diagnostic procedures should
consist of neck ultrasonography to look for possible con-
comitant locoregional disease, thin-cut CT neck, thorax, and
abdomen to look for other distant metastases and MRI brain
for small brain metastases. FDG-PET may also be employed
because it helps to localize disease and prognosticate patient
risk [36]. For patients with neoplastic foci and high FDG
uptakes, local therapy such as radical resection, RFA might
be considered as these high FDG-uptake foci are likely
to be more aggressive, less differentiated and have higher
growth rate [37]. In terms of measuring treatment response,
the response evaluation criteria in solid tumors (RECIST)
criteria are often used. This is carried out by repeating
standardized imaging (usually CT or MRI) every 6 months.
Interestingly, there is no evidence to suggest that novel
treatment such as targeted therapy should be better given at
an early stage than a later stage when the tumor might be
larger in size. As most patients with RAI-refractory disease
might be asymptomatic for a long period of time, the benefits
of targeted therapy must not be outweighed by the drug
toxicities and side effects. Therefore, targeted drug is usually
commenced when there is documented disease progression
by standardized imaging.
3. Potential Molecular Targets
Figure 1 shows the main signaling pathways involved in
thyroid oncogenesis [15]. Since rearrangements of RET (or
RET/PTC) and point mutations of RAS and BRAF are now
believed to be initiating events in the carcinogenesis of PTC,
most new targeted drugs have the ability of inhibiting the
MAPK pathway and angiogenesis. RET/PTC rearrangements
are found more frequently in classical PTC whereas RAS
point mutations are mostly found in the follicular variant of
PTC. BRAF mutations are mostly found in less differentiated
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Figure 1: The main signaling pathways involved in thyroid carcinogenesis are the MAPK and PI3K-AKT pathway (reproduced with
permission) [15].
or tall-cell variant of PTC. The PI3K pathway may also be
activated in some PTC. Other potential targets would be the
angiogenic factors like various vascular endothelial growth
factors (VEGF 1 and 2), fibroblast growth factor (FGF),
and platelet-derived growth factor (PDGF). In vitro studies
showed that anti-VEGF therapy could delay DTC growth
[35]. Table 1 shows the relationship between various targeted
drugs and their molecular targets.
4. New Molecular Targeted Therapy
Table 2 lists the results of various published trials for
new targeted therapy in RAI-refractory thyroid carcinoma.
Sorafenib was one of the first agents studied in RAI
refractory PTC. It is an oral multi-tyrosine kinase inhibitor
with multiple targets, including VEGF-R 1 to 3, PDGF-R,
RET/PTCs, and BRAF. Two American studies have published
the results of using sorafenib 400mg twice daily in advanced
PTC [19, 20]. Gupta-Abramson et al. reported the first phase
II study in advanced PTC. Of the 18 patients with advanced
PTC who received treatment for a minimum of 16 weeks,
4 out of 18 patients had partial response and 10 had stable
disease. In this study, the median progression-free survival
was 84 weeks [19]. Kloos et al. reported another phase II
study on 41 patients with metastatic papillary thyroid cancer.
Of these patients, 15% had partial response and 56% had
stable disease lasting for more than 6 months. The median
progressive free survival was 15 months [20]. Adverse events
were common, most frequent being fatigue (60–74%), hand
foot syndrome (58–83%), diarrhea (68–73%), and muscle
pain (28–57%) [19, 20]. Most of them were grade 1 or 2,
and could be managed with dose reduction or drug holiday.
It is interesting to note that about half the patients had
to have dose reduction to improve compliance and control
toxicity. Total withdrawal of treatment due to grade 3 or
worse adverse events were not uncommon (about 16.6%)
[19]. Since then, 3 other studies from Europe were published.
In a Netherland’s study of 30 patients with DTC, 25% of
patients achieved partial response. The response rate did
not appear to be influenced by gender, age, initial stage,
or presence of BRAF mutation. However, the radiological
response was worse in patients with bone metastases [21].
The authors also studied the possibility of reinduction of
RAI uptake after starting the drug but no reinduction was
observed [21]. A UK study evaluated 19 patients with DTC
treated with sorafenib 400mg twice daily and the partial
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Table 1: Kinase inhibitor activities of target therapies on thyroid cancer [16–18].
Drug
Inhibitory concentration 50 [IC50] (nmol/L)
VEGFR-1 VEGFR-2 VEGFR-3 RET BRAFV600E PDGFR-β Kit Others
Sorafenib 26 90 20 49 25 57 68
Axitinib 1.2 0.25 0.29 2 1.7
Motesanib 2 3 6 59 84 8
Sunitinib 2 9 17 41 39 1–10
Pazopanib 10 30 47 84 74
Lenvatinib (E7080) 22 4 5 35 39 FGFR1 (46)
Cabozantinib (XL-184) 0.035 4 cMET (1.8)
Vandetanib 1600 40 110 130 EGFR (500)
Gefitinib >10000 3700 EGFR (33)
Selumetinib MEK1 (14)
Dabrafenib 0.8
response was 18% at 12 months [23]. Another multicenter
study conducted in Spain on metastatic DTC reported the
response rate in DTC and PTC were 19% (3 out of 16
patients) and 14% (1 out of 7 patients), respectively. The
median progression free survival was 13.5 months in patients
[24]. These results appeared comparable to those reported in
the two US studies.
In view of the drug toxicities, some authors attempted
to reduce the standard dose and evaluated its efficacy.
Chen et al. evaluated the efficacy of low dose sorafenib
(200mg twice daily) on 9 patients with RAI refractory
pulmonary metastases. After three months of treatment, the
partial response (by RECIST criteria) was 33% and stable
disease was achieved in 44% of patients. All adverse events
were grade 1 or 2. From this study, it appeared that low
dose sorafenib could equally achieve satisfactory response
in RAI-refractory PTC [22]. Based on initial success in
sorafenib, a phase III international randomized controlled
trial is currently underway to evaluate it in progressive
RAI-refractory metastatic DTC. In this trial, patients are
randomized into the placebo arm and drug arm and the
primary endpoint is progression-free survival. The final
results are awaiting. (NCT00984282).
Axitinib is an oral, potent selective inhibitor of VEGFRs
1, 2, and 3. It is selectively less potent in inhibiting platelet
derived growth factor receptor beta and c-KIT. Cohen
et al. published a phase II study on 60 patients with
advanced thyroid cancer. Thirty patients with PTC received
axitinib 5mg twice daily oral. Eight patients (26.7%) had
partial response. Stable disease lasting for more than 16
weeks was observed in 12 patients (40%). Overall, the
median progression-free survival was 18.1 months. Thirty-
two patients discontinued axitinib treatment either because
of lack of efficacy (10 patients), or adverse effect (8 patients).
Hypertension, proteinuria, and fatigue were most common
grade 3 or worse events [25].
Motesanib (AMG-706) is a novel oral inhibitor of
multiple tyrosine kinases, including VEGF receptors, PDGF
and KIT. In an open label phase 2 trials, 93 patients with
progressive, locally advanced, or metastatic, RAI-refractory
DTC were prescribed with 125mg motesanib once daily
orally. Fifty-seven (61%) patients had PTC. The objective
radiological response assessed was 14%. Of these, 67%
achieved stable disease while 35% maintained stable disease
for 24 or more weeks. In 75 patients whom had Tg assay,
61 (81%) had reduction in Tg levels. The authors found a
significant correlation between the drop in baseline Tg and
radiological response rate. Similar to other drugs, adverse
effects were a major concern. 94% of all patients experienced
adverse events, and 62% had grade 3 or above adverse events.
The most common adverse events were hypertension (25%)
or diarrhea (13%) There were 2 treatment-related deaths;
both were due to pulmonary hemorrhage [26].
Sunitinib is a multitargeted tyrosine kinase inhibitor
of VEGFR type 1 and 2, PDGFR ∂, and β, c-Kit, FLTF,
and RET. In a phase II study, 37.5mg daily sunitinib was
prescribed continuously to 35 patients with FDG-avid, RAI-
refractory DTC or medullary thyroid carcinoma (MTC).
28% of patients with DTC achieved a RECIST response
assessed by 3 monthly CT scan. The median time to progress
was 12.8 months in this series. The functional response was
also analyzed in this study. In 19 patients with DTC who
underwent PET/CT scan before and after 7 days of sunitinib
therapy, the percentage change of SUV were −13.5%, 17.5%,
and 9.0% for patients with RECIST response, with stable
disease and with progressive disease respectively. There was a
significant correlation between SUV changes and changes in
RECIST criteria (P = 0.005). Despite satisfactory functional
and RECIST response, hematological and other treatment-
related adverse events were also common. Upto 34% of
patients suffered grade 3 or worse hematological side effects
including leukopenia, neutropenia. Other common adverse
effects (≥grade 3) including diarrhea (17%), hand foot
syndrome (17%), and fatigue (11%) [27]. Cohen et al.
reported another series of 43 patients with either DTC or
MTC. In 37 patients with DTC, response rate was 13% and
68% had stable disease. Grade 3/4 haematological adverse
effect were comparably common [28].
Pazopanib (Votrient) is a tyrosine kinase inhibitor target-
ing VEGFR, PDGF, and c-KIT. It has an antiangiogenic effect
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Table 2: Study on target therapy in radioiodine-refractory papillary thyroid cancer.
Author Study Agent
Number of patients
[type]
Result
Response rate
(%)
Stabilization
(%)
Progression-free
survival
(months)
Discontinuation
due to adverse
effect
Gupta-Abramson
et al. [19]
Phase II Sorafenib
30 [DTC and MTC]
(i) DTC: 27/30
(ii) PTC: 18/30
23%
25.9%
22.2%
53%
55.6%
61.1%
18.2 (79 weeks)
19.3 (84 weeks)
16.7%
Kloos et al. [20] Phase II Sorafenib 41 [PTC] 15% 56% (≥6 months) 15 —
Hoftijzer et al.
[21]
Phase II Sorafenib
31 [DTC]
PTC: 14/31
25% 34% (26 weeks) 13.3 (58 weeks) 19.4%
Chen et al. [22] Phase II Sorafenib 9 [PTC] 33% 44% 9.6 (42 weeks) 0
Ahmed et al. [23] Phase II Sorafenib
34 [MTC and DTC]
PTC: 19/34
15%
18%
74% (6 months) — 5.9%
Capdevila et al.
[24]
Phase II Sorafenib
34∗∗
(i) DTC: 16/34
(ii) PTC: 7/34
32%
19%
14%
41% (6 months)
50%
43%
13.5 —
Cohen et al. [25] Phase II Axitinib
60 [DTC]
PTC: 30/60
30%
26.7%
38% (≥16 weeks)
40%
18.1 13%
Sherman et al.
[26]
Phase II Motesanib
93 [DTC]
PTC: 57/93
14% 35% (24 weeks) 9.3 13%
Carr et al. [27] Phase II Sunitinib
35 [DTC and MTC]
(i) DTC: 28/35
(ii) PTC: 18/35
31%
28%
46%
68%
12.8 11.4%
Cohen et al. [28] Phase II Sunitinib 31 [DTC] 13% 68% — —
Bible et al. [29] Phase II Pazopanib
37 [DTC]
PTC: 15/37
49%
33%
— 11.7 5.4%
Sherman et al.
[30]
Phase II Lenvatinib
58 [DTC]
PTC: 43/58
50% 36% 13.3 23%
Cabanillas et al.
[31]
Phase II Cabozantinib 15 [DTC] 53% 40% — —
Leboulleux et al.
[32]
RCT,
phase II
Vandetanib
72 versus 73 [DTC]
PTC: 25 versus 24
8.3% versus 5.5% 56% versus 36%∗
11.1 versus 5.8∗
16.2 versus 5.9
33% versus 6%
Pennell et al. [33] Phase II Gefitinib
27∗∗
PTC: 11/27
0% 24% (6 months) 3.7 7.4%
Hayes et al. [34] Phase II Selumetinib 32 [PTC] 3% 36% (24 weeks) 7.4 —
Falchook et al.
[35]
Phase I Dabrafenib 14 [PTC] 21.4% — — 0
DTC: differentiated thyroid cancer, PTC: papillary thyroid cancer, MTC: medullary thyroid cancer; RCT: randomized controlled trial.
∗P < 0.05.
∗∗Included differentiated, medullary, and anaplastic thyroid carcinoma.
on RAI-refractory DTC. In a phase II study on 37 patients
with progressive radioiodine refractory DTC over previous
6 months, partial response was achieved in 18 patients.
Response rate was 49% and 33% (5 out of 15%) in patients
with DTC and PTC, respectively. 66% of patients were likely
to respond lasting formore than 1 year. The response rate was
highest among reports of different agent. Adverse effects were
common but generally well tolerate. Grade 3 or worse adverse
effect was not common, and the commonest was deranged
liver function tests (4 patients had raised ALT concentration).
Two patients had serious hemorrhagic events (grade 3 lower
gastro-intestinal bleeding, and grade 4 intracranial bleeding
in the absence of brain metastasis or hypertension) and so
had to discontinue treatment [29].
Lenvatinib (E7080) is an oral tyrosine kinase inhibitor
targeting VEGFR 1–3, FGFR 1–4, RET, KIT, and PDGFR β.
In an international phase II study, 58 patients with advanced
progressive DTC were enrolled. Half of them achieved
partial response on assessment. For the subgroup which had
prior VEGFR inhibitors, 41% had a response whereas those
without prior treatment, 54% had a response. However,
because adverse effect was common, 23% of patients had to
withdraw and 35% had to have a dose reduction [30].
Cabozantinib (XL84) is an oral potent inhibitor of cMET
(MET is a membrane receptor that is essential for embryonic
development and wound healing), VEGFR2, and RET and
is currently undergoing a clinical trial. The results of the
phase I trial of this drug appeared promising with 8/15 (53%)
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patients having confirmed partial response and 6 (40%) had
stable disease [31]. It is worth noting that the majority of
these patients had prior VEGFR inhibitors. Grades 3, and 4
adverse effects were comparable to other VEGFR inhibitors
and included diarrhea (20%), hypertension (13%), and hand
foot syndrome (13%) [31].
Vandetanib, a tyrosine kinase inhibitor of RET, VEGFR,
and EGFR signaling, was the first targeted therapy subjected
to large scale multicenter randomized clinical trial [32]. 145
patients with radioiodine refractory differentiated thyroid
cancer were enrolled into the trial. Seventy-two patients,
including 25 with PTC, were allocated to vandetanib 300mg
per day group and 73 patients, including 24 with PTC
were allocated to placebo group. Patients in vandetanib
group (median: 11.1 months (95% CI 7.7–14.0)) had longer
progression-free survival than placebo group [median: 5.9
months (95% CI 4.0–8.9) (P = 0.017). For patient with PTC,
median progression-free survival was 16.2 months (95% CI
8.4–22.6) in vandetanib group and 5.9 months (95% CI
3.0–11.5) in placebo group. Although it was not statistically
significant, there was a tendency for clinical benefit (Hazard
ratio: 0.52, 95% CI 0.26–1.02, P = 0.056). However, there
was no difference in overall survival (Hazard ratio: 0.83, 95%
CI 0.52–1.33, P = 0.42). Most frequent adverse events were
diarrhea (74%) and hypertension (34%). The incidence of
grade 3 or worse adverse events were higher in vandetanib
group (53%, 39/73 patients) than placebo group (19%, 14/72
patients), while the commonest were QTc prolongation
(14%) and diarrhea (10%) [32].
Since EGFR mutations were found in some PTC, Gefi-
tinib, an inhibitor of EGFR tyrosine kinase, had been evalua-
ted in a phase II study for advanced PTC. Pennell et al.
reported the results of 27 patients with 11 of them suffering
from PTC. There was no objective response observed. 24%
had stable disease after 6 months of treatment. Five patients
with stable disease had significant drop in thyroglobulin
(>90% drop) maintained over 3 months. However, no
patient achieved partial response by criteria. The authors
concluded that this drug had limited biological activity of
around 12% only [33].
Other than antiangiogenic therapies, drugs targeting
specific molecular pathway, namely MAPK and PI3K, were
studied in phase I, and II studies. Selumetinib is a selec-
tive oral non-ATP competitive small molecule inhibitor of
MAPK kinases, MEK 1/2. In in vitro studies, Selumetinib
was potent in PTC cell line with V600E BRAF mutation.
It had been recently evaluated in a multicenter phase II
study in patient with radioiodine refractory papillary thyroid
carcinoma. Selumetinib 100mg twice daily was prescribed to
patients with document progression in the last 12 months.
Only 1 patient (3%) achieved partial response and 21 (54%)
had stable disease. Common grade 3 to 4 toxicities included
rash (18%), fatigue (8%), diarrhea (5%), and peripheral
edema (5%). In BRAF evaluated patient, BRAF mutant had
a longer median progression free survival than BRAF wide-
type tumor, though it was not statistically significant (33
versus 11 weeks, P = 0.3) [34].
In a recent published phase I trial, Dabrafenib, inhibitor
of BRAF kinase for BRAF mutant, had showed its anti-
tumor activity in 14 patients with BRAF mutant PTC. Three
of nine assessable patients achieved partial response. Its
adverse effect was less common andmore tolerable. Themost
common grade 2 or worse adverse effects were cutaneous
squamous cell carcinoma (11%), fatigue (8%), and pyrexia
(6%) [35].
In addition to agents which target MAPK and PI3K-
AKT pathways, mTOR inhibitors have been widely studied
recently. In vitro studies, mTOR pathway activation have
been found in aggressive and BRAF mutated PTC [38, 39].
Phase I study of daily everolimus plus low dose weekly
cisplatin reported 1 out of 4 patients achieved prolong stable
disease for 6 months [40]. Sherman et al. reported phase II
study on use of combination of sorafenib and temsirolimus
in 37 patients radioiodine refractory thyroid carcinoma.
21.6% patients had partial response and 56.7% had stable
after median time on treatment of 206 days [41].
Studies on combination of target therapy like everolimus/
lenalidomide, pazopanib/GSK1120212 (MEK inhibitor),
and pimasertib (MEK inhibitor)/SAR245409 (PI3K/mTOR
inhibitors) are ongoing and hopefully, results would become
available in the near future [42–44].
Majority of studies focused on patients with PTC or small
subgroup of follicular thyroid carcinoma (FTC) patients
(Table 2); current evidences on treatment specific on FTC
were limited. Applicability and efficacy of target therapies on
patient with follicular thyroid carcinoma have to be further
evaluated.
5. Redifferentiation of RAI-Refractory
Thyroid Carcinoma
Redifferentiation remains an ongoing area of research in
RAI-refractory thyroid carcinoma because development of
de-differentiated phenotype of DTC leads to loss or absence
of radioiodine uptake ability. Redifferentiating agents could
potentially reactivate the RAI uptake ability of thyroid
carcinoma. Retinoids, chemically related to Vitamin A, were
the first widely studied agents for potential application on
redifferentiation in radioiodine refractory thyroid cancer.
Early in vitro studies showed that decreased expression of
retinoic acid receptor in thyroid cancer cell [45]. Treatment
with retinoids could upgrade the sodium-iodine symporter
(NIS) and thus induce redifferentiation and iodine uptake
by tumor cell. Gru¨ning et al. reported their series on 14
RAI-refractory patients and showed that 2/14 showed slightly
increased uptake [46]. Similar results have been found by
other authors. Short et al. reported the results of 16 patients
with RAI uptake negative DTC. Patients were prescribed oral
isotretinoid 1.5mg/kg/day for 8 weeks. RAI scan repeated
2 weeks later reviewed only 1/16 (6.25%) patient had
increased radio-iodine uptake [47]. Simon et al. reported
a more promising result of using 13-cis-retinoic acid as a
sole treatment. Fifty patients with RAI-refractory DTC were
treated with 13-cis-retinoic acid at dosage of 1.5mg/kg daily
over 5 weeks. Thirteen (26%) showedmarked increase in RAI
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uptake while 8 patients (16%) showed mild increased in RAI
uptake in the post-therapy scan. Tumor size was assessed in
37 patients and of these, 6 had tumor regression while 22 had
static disease. As a whole, 19 (38%) patients showed either
response or stable in clinical response. However, further
analysis reviewed that increased RAI uptake did not always
correlate with clinical response [48]. More recently, Oh et
al. incorporated retinoic acid into RAI ablation to treat RAI
refractory PTC. Oral isotretinoid was prescribed for 6 weeks
at 1–1.5mg/kg daily and then followed by single dose of RAI.
At 6-month follow up, 1 patient showed completed response,
9 had partial response, 9 had stable and 28 had progressive
disease. Overall response rate was 21.3% [49].
Due to the limited benefits, routine use of retinoic acid
alone is not recommended. Preliminary study showed en-
lightening clinical response in refractory cancer results
only in combination therapy. Therefore, further studies
are indicated to evaluate its clinical application, dosage,
duration, and combination regimen.
Thiazolidinedione, an antidiabetic medication, is ano-
ther potential redifferentiation agent. It acts as a peroxisome
proliferator-activated receptor gamma agonist. It was shown
to have both redifferentiation and anti-proliferative effects in
in vitro study of thyroid cancer cells [50]. In an open phase
II trial of 20 patients with Tg-positive RAI-refractory DTC,
25% (5/20) regained RAI uptake. 60% (12/20) had stable dis-
ease and 15% (3/20) had reduction in tumormarker. Overall,
5 patients had a partial response in terms of decreased Tg or
positive RAI uptake on scan. However, no complete or partial
response was noted in any patients according to RECIST
criteria [51]. Other agents, including histone deacetylase
inhibitor, (e.g., valproic acid, trichostatin, and depsipeptide),
DNA demethylating agents, (e.g., 5-azacytidine), and arsenic
trioxide, had shown differentiation inducing properties in
thyroid cancer cells in in vitro studies [52–55]. Potential
clinical application had to be further validated by future
studies.
6. Conclusion
Managing RAI-refractory advanced or metastatic PTC
remains challenging. Given the fact that RAI is of little benefit
in this group of patients, various treatment options such
as observation, symptomatic control, surgery, local ablative
therapy, metastectomy, and EBRT might be considered. New
molecular targeted drugs including tyrosine kinase inhibitors
and redifferentiation drugs are new promising therapeutic
options for this specific group of patients.
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